EDIT Should I Buy

TD Cowen notes that Editas Medicine presented "compelling preclinical data" at EAS detailing EDIT-401's 90% reduction in low-density lipoprotein cholesterol, apolipoprotein B and lipoprotein(a) in non-human primates, supporting a broad mechanism of action. A clinical trial notification is expected in mid-2026 and human proof of concept by year-end. The Phase 1/2 is expected to be a two-part study consisting of dose-finding and placebo-controlled dose expansion in heterozygous familial hypercholesterolemia patients. A single pivotal Phase 3 trial is expected to follow, TD Cowen adds. The firm keeps a Buy rating on the shares.